Severe haemophilia A with haemarthrosis improved on emicizumab: A case report

Introduction Severe haemophilia A is associated with serious spontaneous bleeding in muscles, soft tissues, and joints. Haemarthrosis, bleeding into joints, is a serious complication of haemophilia. Emicizumab is a novel non-factor replacement agent for preventing or reducing the frequency of bleeding episodes in adults and children with haemophilia A with or without inhibitors. Case presentation In this case report, we discuss the case of a 10-year-old child with severe haemophilia A without inhibitors. He was initially managed with on-demand and prophylactic plasma-derived factor VIII and, after complications due to haemarthrosis, emicizumab. Treatment with emicizumab was associated with improved quality of life. Conclusion This case report shows that disease-related complications, particularly haemarthrosis, and health-related quality of life can be improved after the initiation of emicizumab.